Biotech & Medical Venture Deals Roundup
by Adam Rubenstein
Locus Pharma (Blue Bell, PA) is focused on the development of novel small molecule drug therapies raised a $30.2M Series D financing. The round was led by Novartis Bioventures, Prism Venture Partners and HBM BioVentures. Other participants included S.R. One Capital and L Capital Partners.
InnerPulse (Research Triangle Park, NC) a developer of implantable defibrillators raised $50M in a Series C financing. Investors included Johnson & Johnson Development Corp., Medtronic, Synergy Life Science Partners, Ascent Biomedical Ventures, Delphi Ventures and Frazier Healthcare Ventures.
Omeros (Seattle, WA) a biopharmaceutical company focused on improving joint function following arthroscopic surgeries raised $63M in a Series E financing. Investors included Aravis Ventures, Arch Venture Partners, American Financial Group, Grosvenor Funds, Novartis Venture Fund, Southern Cross Capital, Stanley Medical Research Institute, and Trevi Health Ventures.
Prosensa (Netherlands) a biotech company focused on RNA interference therapeutics for muscular dystrophies raised $18 million in Series A funding. The deal was led by Abingworth Management and Life Science Partners and were joined by return backer Medsciences Capital.
Ception Therapeutics (Malvern, PA) a drug company developing anti-inflammatories, raised a $63M Series C round. The financing was led by Essex Woodlands Health Ventures, and was joined by Investor Growth Capital, MDS Life Sciences, New Science Ventures and Aperture Venture Partners.
Targanta (Cambridge, MA) developer of antibacterial pro-drugs raised closed a $70M Series C financing led by Brookside Capital, Skyline Ventures, Radius and OrbiMed Advisors. Existing investors Seaflower Ventures, VenGrowth and the Canadian Medical Discoveries Fund also participated.
4-Antibody (Basel, Switzerland) a biopharmaceutical company developing optimal therapeutic antibody drugs has raised around $13.7M in additional Series A funding, bringing the round total to $18.5 million. The round was led by Advent Venture Partners and was joined by existing backers Life Sciences Partners, BioMedinvest AG, Grazia Equity and Mulligan Biocapital.
Proacta (San Diego, CA) a clinical stage oncology company closed a $35M Series B financing. Clarus Ventures, a new investor, led the round, and was joined by Delphi Ventures. Existing investors are Alta Partners, GBS Venture Partners and the New Zealand Venture Investment Fund as well as pharmaceutical companies Genentech and Roche.
PREVIOUS VENTURE DEAL ROUNDUPS:
- February 09, 2007
- February 03, 2007
- January 20 2006
- December 16, 2006
- December 09, 2006
____________________
Locus Pharma (Blue Bell, PA) is focused on the development of novel small molecule drug therapies raised a $30.2M Series D financing. The round was led by Novartis Bioventures, Prism Venture Partners and HBM BioVentures. Other participants included S.R. One Capital and L Capital Partners.
InnerPulse (Research Triangle Park, NC) a developer of implantable defibrillators raised $50M in a Series C financing. Investors included Johnson & Johnson Development Corp., Medtronic, Synergy Life Science Partners, Ascent Biomedical Ventures, Delphi Ventures and Frazier Healthcare Ventures.
Omeros (Seattle, WA) a biopharmaceutical company focused on improving joint function following arthroscopic surgeries raised $63M in a Series E financing. Investors included Aravis Ventures, Arch Venture Partners, American Financial Group, Grosvenor Funds, Novartis Venture Fund, Southern Cross Capital, Stanley Medical Research Institute, and Trevi Health Ventures.
Prosensa (Netherlands) a biotech company focused on RNA interference therapeutics for muscular dystrophies raised $18 million in Series A funding. The deal was led by Abingworth Management and Life Science Partners and were joined by return backer Medsciences Capital.
Ception Therapeutics (Malvern, PA) a drug company developing anti-inflammatories, raised a $63M Series C round. The financing was led by Essex Woodlands Health Ventures, and was joined by Investor Growth Capital, MDS Life Sciences, New Science Ventures and Aperture Venture Partners.
Targanta (Cambridge, MA) developer of antibacterial pro-drugs raised closed a $70M Series C financing led by Brookside Capital, Skyline Ventures, Radius and OrbiMed Advisors. Existing investors Seaflower Ventures, VenGrowth and the Canadian Medical Discoveries Fund also participated.
4-Antibody (Basel, Switzerland) a biopharmaceutical company developing optimal therapeutic antibody drugs has raised around $13.7M in additional Series A funding, bringing the round total to $18.5 million. The round was led by Advent Venture Partners and was joined by existing backers Life Sciences Partners, BioMedinvest AG, Grazia Equity and Mulligan Biocapital.
Proacta (San Diego, CA) a clinical stage oncology company closed a $35M Series B financing. Clarus Ventures, a new investor, led the round, and was joined by Delphi Ventures. Existing investors are Alta Partners, GBS Venture Partners and the New Zealand Venture Investment Fund as well as pharmaceutical companies Genentech and Roche.
PREVIOUS VENTURE DEAL ROUNDUPS:
- February 09, 2007
- February 03, 2007
- January 20 2006
- December 16, 2006
- December 09, 2006
____________________
posted by Nico at
7:18 PM
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home